148 related articles for article (PubMed ID: 24096622)
21. Dual p16 and Ki-67 Expression in Liquid-Based Cervical Cytological Samples Compared to Pap Cytology Findings, Biopsies, and HPV Testing in Cervical Cancer Screening: A Diagnostic Accuracy Study.
Prigenzi KCK; Heinke T; Salim RC; Focchi GRA
Acta Cytol; 2018; 62(2):104-114. PubMed ID: 29566392
[TBL] [Abstract][Full Text] [Related]
22. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
[TBL] [Abstract][Full Text] [Related]
23. p16 INK4A is a strong biomarker for cervical intraepithelial neoplasia and invasive cervical carcinoma: a reappraisal.
Haidopoulos D; Partsinevelos GA; Vlachos GD; Rodolakis A; Markaki S; Voulgaris Z; Diakomanolis E; Antsaklis A
Reprod Sci; 2009 Jul; 16(7):685-93. PubMed ID: 19372590
[TBL] [Abstract][Full Text] [Related]
24. Heat shock protein 27 and p16 immunohistochemistry in cervical intraepithelial neoplasia and squamous cell carcinoma.
Tozawa-Ono A; Yoshida A; Yokomachi N; Handa R; Koizumi H; Kiguchi K; Ishizuka B; Suzuki N
Hum Cell; 2012 Mar; 25(1):24-8. PubMed ID: 22302674
[TBL] [Abstract][Full Text] [Related]
25. P16 and Ki-67 expression improves the diagnostic accuracy of cervical lesions but not predict persistent high risk human papillomavirus infection with CIN1.
Zhong P; Li J; Gu Y; Liu Y; Wang A; Sun Y; Lu L
Int J Clin Exp Pathol; 2015; 8(3):2979-86. PubMed ID: 26045807
[TBL] [Abstract][Full Text] [Related]
26. Good performance of p16/Ki-67 dual-stain cytology for detection and post-treatment surveillance of high-grade CIN/VAIN in a prospective, cross-sectional study.
Liu W; Gong J; Xu H; Zhang D; Xia N; Li H; Song K; Lv T; Chen Y; Diao Y; Jao J; Dai S; Zhao P; Yao Q
Diagn Cytopathol; 2020 Jul; 48(7):635-644. PubMed ID: 32275355
[TBL] [Abstract][Full Text] [Related]
27. [Clinical value of p16
Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
[No Abstract] [Full Text] [Related]
28. [Biopsy in the diagnosis of human papilloma virus in the context of a vaccine].
Curiel-Valdés Jde J
Cir Cir; 2008; 76(1):1-3. PubMed ID: 18492413
[No Abstract] [Full Text] [Related]
29. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer.
Murphy N; Ring M; Heffron CC; King B; Killalea AG; Hughes C; Martin CM; McGuinness E; Sheils O; O'Leary JJ
J Clin Pathol; 2005 May; 58(5):525-34. PubMed ID: 15858126
[TBL] [Abstract][Full Text] [Related]
30. p16/Ki-67 immunostaining in the triage of young women with LSIL, ASC-US, and ASC-H cytology.
Dovnik A; Repše-Fokter A
Diagn Cytopathol; 2020 Jan; 48(1):96-97. PubMed ID: 31714671
[No Abstract] [Full Text] [Related]
31. Clinical Utility of CINtec PLUS Triage in Equivocal Cervical Cytology and Human Papillomavirus Primary Screening.
McMenamin M; McKenna M; McDowell A
Am J Clin Pathol; 2018 Oct; 150(6):512-521. PubMed ID: 30169728
[TBL] [Abstract][Full Text] [Related]
32. [Importance of immunohistochemical studies in the diagnosis and the prognostic evaluation of cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix. Review].
García-Tamayo J; Molina J; Blasco-Olaetxea E
Invest Clin; 2009 Jun; 50(2):241-50. PubMed ID: 19662819
[TBL] [Abstract][Full Text] [Related]
33. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis.
Tsoumpou I; Arbyn M; Kyrgiou M; Wentzensen N; Koliopoulos G; Martin-Hirsch P; Malamou-Mitsi V; Paraskevaidis E
Cancer Treat Rev; 2009 May; 35(3):210-20. PubMed ID: 19261387
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical expression of p16(INK4A) in normal uterine cervix, nonneoplastic epithelial lesions, and low-grade squamous intraepithelial lesions.
Focchi GR; Silva ID; Nogueira-de-Souza NC; Dobo C; Oshima CT; Stavale JN
J Low Genit Tract Dis; 2007 Apr; 11(2):98-104. PubMed ID: 17415114
[TBL] [Abstract][Full Text] [Related]
35. When to use dual staining in cervical cancer screening?
Tjalma WAA
J Cancer Res Ther; 2022; 18(1):318-319. PubMed ID: 35381812
[No Abstract] [Full Text] [Related]
36. Evaluation of p16/Ki-67 dual staining in the detection of cervical precancer and cancer in China.
Zhang SK; Jia MM; Zhao DM; Wu ZN; Guo Z; Liu YL; Guo PP; Chen Q; Cao XQ; Liu SZ; Chen W; Sun XB
Cancer Epidemiol; 2019 Apr; 59():123-128. PubMed ID: 30739069
[TBL] [Abstract][Full Text] [Related]
37. p16INK4a immunoexpression: surrogate marker of high-risk HPV and high-grade cervical intraepithelial neoplasia.
Kalof AN; Cooper K
Adv Anat Pathol; 2006 Jul; 13(4):190-4. PubMed ID: 16858153
[TBL] [Abstract][Full Text] [Related]
38. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results.
Bergeron C; Ikenberg H; Sideri M; Denton K; Bogers J; Schmidt D; Alameda F; Keller T; Rehm S; Ridder R;
Cancer Cytopathol; 2015 Jun; 123(6):373-81. PubMed ID: 25891096
[TBL] [Abstract][Full Text] [Related]
39. The use of p16 as a marker for cervical cancer precursor lesions.
O'Connor DM
J Low Genit Tract Dis; 2007 Apr; 11(2):67-8. PubMed ID: 17415108
[No Abstract] [Full Text] [Related]
40. p16/Ki-67 dual-stained cytology testing may predict postpartum outcome in patients with abnormal papanicolaou cytology during pregnancy.
Trutnovsky G; Kolovetsiou-Kreiner V; Reich O
Acta Cytol; 2014; 58(3):293-6. PubMed ID: 24642606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
